PRNewsWire
25 Jun 2026, 08:53 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The TACTI-004 trial of eftilagimod alfa failed to meet its primary efficacy endpoints. — Failure of a primary efficacy endpoint for a lead drug candidate is a material negative catalyst for a biotech company's valuation.
-0.80Immutep is facing a securities fraud class action lawsuit alleging it concealed the TACTI-004 trial results. — Legal proceedings for fraud create financial liability and undermine management credibility and investor trust.
-0.50Which stocks this story touches
The company is the subject of a securities fraud class action lawsuit.
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding trial results.
The company is the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
